Adaptyx Biosciences has raised $14 million in seed financing to advance the development of its multi-analyte biowearable platform, bringing total funding to $23 million. Interlagos led the Menlo Park-based startup's round with participation from Overwater Ventures, Starbloom Capital, Stanford University, the Chan Zuckerberg Biohub, Hyperlink Ventures, Cantos Ventures, Humba Ventures, and Seaside Ventures.
The company is developing a wearable patch that continuously tracks a wide range of biochemical signals, extending beyond glucose to include hormones, drugs, proteins, and electrolytes. Its platform integrates synthetic DNA-based molecular switches with AI-powered analytics to deliver continuous molecular data and actionable insights.
Adaptyx's Molecular Switch Foundry combines automated molecular design, high-throughput screening, and AI-driven optimization to shorten biosensor development timelines from years to weeks. Applications under development include continuous heart failure monitoring, hormone optimization, drug-level tracking, and personalized wellness.
Founded in 2022 from Stanford University and the Chan Zuckerberg Biohub research of Professors H. Tom Soh and Joseph M. DeSimone, Adaptyx holds an exclusive license to its foundational intellectual property. The new capital will be used to expand R&D, scale the team, and advance clinical trials for its first application.
KEY QUOTES:
"Healthcare suffers from a data deficit. Lab tests are only snapshots of health and don't capture the body's changing physiology, leaving blind spots that prevent addressing many of today's health challenges. Adaptyx gives patients and clinicians a continuous view of what's happening inside the body, transforming previously unseen molecular signals into empowering insights. Our mission is to expand continuous monitoring beyond glucose to include the many molecules that drive human health, creating a rich data pipeline that guides patients and clinicians to make the best decisions at the right time. We're starting with life-saving clinical applications and will ultimately bring this capability to everyone."
Vijit Sabnis, Ph.D., CEO & Co-Founder, Adaptyx
"Each new switch generates structured datasets that make the system smarter and faster, rapidly expanding the analyte library and powering new applications."
Alex Yoshikawa, Ph.D., Chief Science Officer and Co-Founder, Adaptyx
"After 17 years developing this technology in academia, we're ready to bring continuous molecular monitoring from the lab to real patients. The ability to continuously track multiple biomarkers simultaneously is a breakthrough that will transform how we understand human health and improve care for everyone."
Professor H. Tom Soh, Co-Founder and Scientific Advisor, Adaptyx
"Adaptyx's technical expertise in the science of molecular sensing is the bedrock of the business. Engineering a novel device to sense biological datasets fundamentally transforms the way we will measure and deliver healthcare."
Achal Upadhyaya, Founder and CEO of Interlagos Capital and Adaptyx Board Member
"Adaptyx is exactly the kind of category-defining innovation healthcare has been waiting for. This team isn't chasing incremental change -- they're re-architecting how we observe physiology, continuously and at scale. By delivering multi-analyte molecular data in a wearable format, Adaptyx turns monitoring into a living layer of care rather than a periodic event. That step-change sets a new bar for what technology can do for patients and clinicians."